Mirum Pharmaceuticals(MIRM)
FOSTER CITY, CA
Pharmaceutical1 H-1B visas (FY2023)Focus: Small Molecules
Mirum Pharmaceuticals is a life sciences company focused on Small Molecules.
Neurology
Funding Stage
PUBLIC
Open Jobs
34
Products & Portfolio (4)
CHOLBAM
cholic acid
Peak
ORAL · CAPSULE
liver. In bile acid synthesis disorders due to SEDs in the biosynthetic pathway, and in PDs including Zellweger spectrum disorders, deficiency of primary bile acids leads to unregulated accumulation of intermediate bile acids and cholestasis. Bile acids facilitate fat digestion and absorption by forming mixed micelles and facilitate absorption of fat-soluble vitamins in the intestine. Endogenous bile acids including cholic acid enhance bile flow and provide the physiologic feedback inhibition of bile acid synthesis. The mechanism of action of cholic acid has not been fully established; however, it is known that cholic acid and its conjugates are endogenous ligands of the nuclear receptor, farnesoid X receptor (FXR). FXR regulates enzymes and transporters that are involved in bile acid synthesis and in the enterohepatic circulation to maintain bile acid homeostasis under normal physiologic conditions.
bile acid synthesis disorders due to single enzyme defects (SEDs) 1
2015
30
CTEXLI
chenodiol
LOE Approaching
ORAL · TABLET
(chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. In CTX, the major bile acid synthesis pathways are disrupted due to partial or total deficiency in sterol 27-hydroxylase encoded by the CYP27A1 gene. CTEXLI may act to replace deficient levels of the endogenous bile acid chenodeoxycholic acid in patients with CTX. Increased chenodiol levels in the enterohepatic bile acid pool restore the activation of farnesoid X receptor (FXR) and downregulate CYP7A1 leading to suppression and reduction of atypical bile acids and bile alcohols including cholestanol and 23S-pentol.
cerebrotendinous xanthomatosis (CTX) in adults
2025
25
LIVMARLI
maralixibat chloride
Peak
ORAL · SOLUTION
(IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum . Pruritus is a common symptom in patients with ALGS or PFIC and the pathophysiology of pruritus in patients with ALGS or PFIC is not completely understood. Although the complete mechanism by which maralixibat improves pruritus in ALGS or PFIC patients is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in serum bile acids [see ] .
cholestatic pruritus in patients 3 months of ageolder with Alagille syndrome (ALGS)cholestatic pruritus in patients 12 months of age+1 more
2021
0
LIVMARLI
maralixibat chloride
Launch
ORAL · TABLET
(IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum . Pruritus is a common symptom in patients with ALGS or PFIC and the pathophysiology of pruritus in patients with ALGS or PFIC is not completely understood. Although the complete mechanism by which maralixibat improves pruritus in ALGS or PFIC patients is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in serum bile acids [see ] .
cholestatic pruritus in patients 3 months of ageolder with Alagille syndrome (ALGS)cholestatic pruritus in patients 12 months of age+1 more
2025
0
Pipeline & Clinical Trials
Livmarli
Alagille SyndromeClinical Trials (1)
NCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
N/Amaralixibat
Alagille SyndromeClinical Trials (1)
NCT04530994A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
N/AValidation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
Alagille SyndromeClinical Trials (1)
NCT02131623Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
N/AN/A
Clinical Trials (1)
NCT03115086The REPLACE Registry for Cholbam® (Cholic Acid)
N/AConfirmatory Testing
Acid Sphingomyelinase DeficiencyPediatric Evaluation and Registry for Liver Cholestasis in Canada
PFIC - Progressive Familial Intrahepatic CholestasisClinical Trials (1)
NCT07411716Pediatric Evaluation and Registry for Liver Cholestasis in Canada
N/APlacebo
Healthy VolunteersClinical Trials (1)
NCT02475317Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
Phase 1Phase 1
Clinical Trials (1)
NCT02287779Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
Phase 1Phase 1
Clinical Trials (1)
NCT02571192A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
Phase 1Phase 2
Clinical Trials (1)
NCT02057718Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
Phase 2LUM001
Alagille SyndromeClinical Trials (1)
NCT01903460Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
Phase 2LUM001
Alagille SyndromeClinical Trials (1)
NCT02047318An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
Phase 2Phase 2
Clinical Trials (1)
NCT02061540Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis
Phase 2Phase 2
Clinical Trials (1)
NCT04729751A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Phase 2LUM001
Alagille SyndromeClinical Trials (1)
NCT02160782Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
Phase 2Maralixibat
Intrahepatic Cholestasis of PregnancyClinical Trials (1)
NCT07389031Maralixibat for Intrahepatic Cholestasis of Pregnancy
Phase 2Volixibat
Primary Sclerosing CholangitisClinical Trials (1)
NCT04663308A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Phase 2Volixibat
Primary Biliary CholangitisClinical Trials (1)
NCT05050136A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Phase 2LUM001
Alagille SyndromeClinical Trials (1)
NCT02057692Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
Phase 2Maralixibat
Biliary AtresiaClinical Trials (1)
NCT04524390Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
Phase 2LUM001
PBCClinical Trials (1)
NCT01904058Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
Phase 2Maralixibat
Cholestatic Liver DiseaseClinical Trials (1)
NCT04168385MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
Phase 2Low dose of MRM-3379
Fragile X SyndromeClinical Trials (1)
NCT07209462Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Phase 2LUM001
Alagille SyndromeClinical Trials (1)
NCT02117713An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Phase 2Phase 2
Clinical Trials (1)
NCT04718961A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
Phase 2Phase 2
Clinical Trials (1)
NCT02321306An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
Phase 2Phase 2
Clinical Trials (1)
NCT02787304Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
Phase 2Brelovitug 300 mg
Chronic Hepatitis D InfectionClinical Trials (1)
NCT06907290A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Phase 2/3Brelovitug
Chronic Hepatitis DClinical Trials (1)
NCT07454837Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Phase 2/3Phase 3
Clinical Trials (1)
NCT03353454A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Phase 3Phase 3
Clinical Trials (1)
NCT03905330A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Phase 3Cholic Acid
Bile Acid Synthesis DefectClinical Trials (1)
NCT01438411Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
Phase 3Phase 3
Clinical Trials (1)
NCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
Phase 3Brelovitug 300 mg
Chronic Hepatitis D InfectionClinical Trials (1)
NCT07200908A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Phase 3Cholic Acids
Infantile Refsum's DiseaseClinical Trials (1)
NCT00007020Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
Phase 3Phase 3
Clinical Trials (1)
NCT04185363An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
Phase 3Cholic acid
Inborn Errors of Bile Acid SynthesisClinical Trials (1)
NCT01115582Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis
Phase 3Blinded CDCA 250 mg TID
CTXClinical Trials (1)
NCT04270682Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
Phase 3Brelovitug 300 mg
Chronic Hepatitis D InfectionClinical Trials (1)
NCT07298330A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Phase 3Livmarli Oral Product
Alagille SyndromeClinical Trials (1)
NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
Phase 4Open Jobs (34)
Intern, Commercial Operations
Zug
Commercial14h ago
Director, Clinical Development
Foster City
Research & Development4d ago
$220K - $240K/yr
Intern, Quality Compliance
Foster City
Quality Assurance5d ago
$35 - $45/hr
Intern, Commercial Operations Communications
Foster City
Commercial5d ago
$35 - $45/hr
Intern, Medical Affairs
Foster City
Medical Affairs5d ago
$35 - $45/hr
Medical Science Liaison, Southeast
Remote
Medical Affairs6d ago
$190K - $210K/yr
Intern, Corporate Development
Foster City
Corporate Functions1w ago
$35 - $45/hr
Intern, IT Support Specialist
Foster City
Corporate Functions1w ago
$35 - $45/hr
Vice President, Commercial Operations International
Zug
Commercial2w ago
Senior Manager, Statistical Programming & Analysis
Foster City
Research & Development2w ago
$190K - $210K/yr
Talent Acquisition Specialist
Foster City
Corporate Functions2w ago
Clinical Trial Manager
Foster City
Research & Development3w ago
$160K - $180K/yr
Specialist, Vendor Compliance
Foster City
Quality Assurance3w ago
$85K - $105K/yr
Executive Director, Clinical Development
Foster City
Research & Development3w ago
$375K - $420K/yr
Director, Clinical Development - GI/Hep/Liver
Foster City
Research & Development3w ago
Manager, Commercial Operations Project Management
Foster City
Commercial3w ago
$140K - $155K/yr
Director, FP&A – Corporate Consolidations and G&A
Foster City
Corporate Functions3w ago
$225K - $250K/yr
Manager, Healthcare Compliance
Foster City
Corporate Functions3w ago
$145K - $160K/yr
Senior Manager, Commercial IT CRM Lead
Foster City
Corporate Functions3w ago
$190K - $205K/yr
Director, GMP Quality Assurance Operations
Foster City
Quality Assurance3w ago
$220K - $235K/yr
Senior Manager, Commercial IT Integration Lead
Foster City
Corporate Functions3w ago
$190K - $205K/yr
Senior Director, Regulatory Affairs CMC
Foster City
Regulatory Affairs4w ago
$280K - $310K/yr
Senior Director, Global Regulatory Affairs
Foster City
Regulatory Affairs1mo ago
$289K - $320K/yr
Senior Manager, Commercial Supply Chain
Foster City
Supply Chain1mo ago
$180K - $190K/yr
Associate Director, Medical Safety Review
Foster City
Research & Development1mo ago
$210K - $225K/yr
Interview Prep Quick Facts
Founded: 2024
Portfolio: 4 approved products, 39 clinical trials
Top TAs: Gastroenterology, Infectious Diseases, Dermatology
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 34 active jobs
Portfolio Health
Launch1 (25%)
Peak2 (50%)
LOE Approaching1 (25%)
4 total products
Therapeutic Area Focus
Gastroenterology
4 marketed12 pipeline
Infectious Diseases
7 pipeline
Dermatology
2 marketed
Rare Diseases
1 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$186M142%
R&D Spend
$103M(55%)4%
Net Income
-$163MCash
$223MHiring Trend
Stable
34
Open Roles
+6
Added
-5
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub